Real-world applications of PARPi maintenance therapy for recurrent ovarian cancer: A single-center study in China
Open Access
- 5 January 2023
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 170, 25-31
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian CancerNew England Journal of Medicine, 2018
- Corrections to “Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”Annals of Oncology, 2018
- Treatment of recurrent ovarian cancerAnnals of Oncology, 2017
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialThe Lancet Oncology, 2017
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian CancerNew England Journal of Medicine, 2016
- What Characterizes Long-term Survivors of Recurrent Ovarian Cancer? Case Report and Review of the LiteratureAnticancer Research, 2016
- TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancerGynecologic Oncology, 2014
- Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish studyGynecologic Oncology, 2014
- The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapyAnnals of Oncology, 2012
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian CancerNew England Journal of Medicine, 2012